Boehringer Ingelheim Cuts U.S. Sales Reps By 30% Before Flomax Generics In 2010
This article was originally published in The Pink Sheet Daily
Yet another pharma slashes sales team in the wake of generic competition and a changing commercial climate.
You may also be interested in...
The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.